NERx Biosciences
Innovation Uncompromised.
Innovation Uncompromised.
NĒRx Biosciences, founded in 2009, is a biotechnology company focused on pioneering innovative cancer therapeutics targeting the DNA damage response. Their dedication to innovation is evident in their slogan, "Innovation Uncompromised." The company has positioned itself as a leader in the biotechnology and health and wellness industries, leveraging its expertise to develop a pipeline of novel therapeutics against targets in the DDR pathway. Their recent milestone includes a significant $2.00M grant investment secured on 08 August 2024 from the National Cancer Institute. This investment underscores the recognition and support from a key player in the healthcare sector, validating the potential of NĒRx Biosciences' approach to cancer therapeutics. This strategic partnership with the National Cancer Institute not only provides financial backing but also signifies a vote of confidence in the company's research and development efforts. NĒRx Biosciences' commitment to advancing cancer treatment through innovative solutions positions them favorably for future growth and success in the biotechnology landscape.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $2.00M | 1 | National Cancer Institute | 08 Aug 2024 |
| Seed Round | $500.00K | 1 |
|
10 Jun 2019 |
No recent news or press coverage available for NERx Biosciences.
We care about your data, and we'd love to use cookies make your experience better.
